pharmatimes.com - News & Jobs now available on your smartphone 

PharmaTimes Magazine
Saturday, January 28, 2012
Where am I? > Skip Navigation LinksHome

NICE final OK extends use of MabThera

NICE has issued final guidance recommending Roche's MabThera as an option when used in combination with a wide range of chemotherapy treatments for advanced follicular lymphoma.

...more UK News

Almirall, BioFocus enter three-year drug discovery alliance

Spain’s Almirall has consolidated its existing relationship with BioFocus, the UK-based drug discovery specialist and Galapagos affiliate, by announcing a three-year research alliance aimed at delivering “drug development candidates directed to a key respiratory target of interest to Almirall”.

...more Clinical News

World NewsSubscribe to RSS

UK NewsSubscribe to RSS

  • NICE final OK extends use of MabThera

    NICE has issued final guidance recommending Roche's MabThera as an option when used in combination with a wide range of chemotherapy treatments for advanced follicular lymphoma.

  • NICE final "no" for Avastin, Erbitux and Vectibix

    NICE has issued final guidance not recommending the use of Roche's Avastin, Merck Serono's Erbitux or Amgen's Vectibix for the treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy.

  • Govt urged to "build on UK’s genomics lead”

    UK patients should be able to benefit from genomic technology which can improve the NHS' understanding of the nature of disease and allow treatment to be tailored to patients' individual genetic make-up, Ministers have been told.

Clinical NewsSubscribe to RSS

  • Covance invests for growth as EPS drop 24% in Q4

    Plans for a sharp increase in IT expenditure and further efforts to expand its commercial footprint during 2012 dampened Covance’s profit forecast for the year ahead, as fourth-quarter revenues came in below the analyst consensus but earnings per share (EPS) met expectations once restructuring and other charges were stripped out.

  • Almirall, BioFocus enter three-year drug discovery alliance

    Spain’s Almirall has consolidated its existing relationship with BioFocus, the UK-based drug discovery specialist and Galapagos affiliate, by announcing a three-year research alliance aimed at delivering “drug development candidates directed to a key respiratory target of interest to Almirall”.

  • Charles River microsite looks for that Eureka moment

    Charles River Laboratories has launched an online community as a forum for scientists to connect, interact and explore ‘Big Ideas’.

see pharmatimes on your smartphone

 

Comment...

"Are KAMs already outdated?"

Geoff Frew,
Managing Editor

Website Search

Search over 18,000 news articles

Job SearchFind your next job

  • e.g. Director, Medical Sales
  • e.g. London
  • e.g. last 2 days
 
Elert Signup!

Popular Tags